RBD5044 not checked
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypertriglyceridemia
- Main trialPhase 2
- “The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat hypertriglyceridemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84).”In the company’s words, NCT07587788 on ClinicalTrials.gov
Other drugs for Hypertriglyceridemia
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- SHR-1918Hengrui · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- PlozasiranArrowhead · Phase 3
- MN-001MediciNova · Phase 2
- SolbinsiranEli Lilly · Phase 2
Coming up1
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Mar 2027 | RBD5044 in Chinese Participants With Hypertriglyceridemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026